ABSTRACT
Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer. Detecting cancer, when the tumor is localized, allows for a more efficient treatment—either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. The clinical sensitivity and specificity, typically defined by the content of biomarkers and their algorithmic interrelationships when running on the platform, are obviously extremely important for the ability of the medical test to identify those patients with and without the disease of interest. A great deal of progress has been made in the field of precision diagnostics of cancer. The complex nature of a developing cancer has made it clear that diagnostic medical devices need to be founded on technologies capable of performing multiplexed biomarker analysis and thereby achieve clinical sensitivities that are much improved compared to the single-plexing tests.
